Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not ...
The goal of this randomized, double-blind, placebo-controlled trial was to assess the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and ...
Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback